Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
Latest Jobs
Exclusive vacancies may not be shown here, please contact Laura on +44 1494 818 026 or for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Laura Marsh
Account Manager
+44 1494 818 026

I just wanted to take this opportunity to say thanks for all Zenopa’s assistance. The level of support and time they gave to me went far beyond my expectations.
Louise, 2015

Bristol-Myers Squibb and Pfizer report positive Eliquis data

23 June 2011 00:00 in Pharmaceutical Company Product News

Bristol-Myers Squibb and Pfizer have revealed that their collaboratively-developed drug Eliquis has demonstrated efficacy among atrial fibrillation (AF) patients in a new clinical trial.

The drug has been trialled in a phase III study called Aristotle, which evaluated the apixaban compound as a means of treating AF sufferers with an elevated risk of stroke.

Eliquis was able to meet its primary goal of non-inferiority to warfarin in preventing stroke and systemic embolism, as well as its secondary endpoint of superior efficacy and reduction of major bleeding events compared to the control drug.

The partners intend to present detailed data on the Aristotle outcome at this year's European Society of Cardiology Congress, which takes place in Paris in August.

European and US regulatory filings will also be submitted for Eliquis in this specification in the third or fourth quarter of 2011.

This comes after Bristol-Myers Squibb and Pfizer received their first regulatory approval for the drug last month, when the European Commission ratified it as a treatment for venous thromboembolic events among orthopaedic surgery patients.ADNFCR-8000103-ID-800591566-ADNFCR

Other news stories from 23/06/2011

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency

© Copyright 2015 Zenopa Ltd